Garrett M. Nash

Consensus Guideline for the Management of Peritoneal Mesothelioma

MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer

Watch and wait in rectal cancer patients with residual mucin on magnetic resonance imaging following neoadjuvant therapy

Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial

Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy

Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer

A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers

Molecular Characterization of Peritoneal Mesotheliomas

A rectal cancer organoid platform to study individual responses to chemoradiation

SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance

SMAD4 loss in colorectal cancer: Correlation with recurrence, chemoresistance, and immune infiltrate.

Readmission After Ileostomy Creation

A Retrospective Review of 126 High-Grade Neuroendocrine Carcinomas of the Colon and Rectum

Adjuvant chemotherapy in rectal cancer: Defining subgroups who may benefit after neoadjuvant chemoradiation and resection: A pooled analysis of 3,313 patients

Consensus Guidelines from The American Society of Peritoneal Surface Malignancies on Standardizing the Delivery of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Patients in the United States

Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: A propensity score analysis

Neither FDG-PET Nor CT Can Distinguish Between a Pathological Complete Response and an Incomplete Response After Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer